SGO 2026 – GSK bucks the B7-H4 trend | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
SGO 2026 – BioNTech’s Enhertu me-too comes up short | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
BackgroundDespite many women learning about endometriosis on social media, posts about the condition often fail to reflect current evidence. With the content and credibility of online health messages being found …
Background/Objectives: Oxidative stress plays an important role in the pathophysiology of endometriosis, contributing to inflammation, immune dysregulation, and lesion progression. This has led to growing interest in antioxidant-based strategies as …
Primary dysmenorrhea is painful menstruation in the absence of pelvic pathology, whereas secondary dysmenorrhea is menstrual pain attributable to an underlying pelvic disease (e.g., endometriosis). Nonsteroidal anti-inflammatory drugs (NSAIDs) are …
Endometriosis Pain Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma, Abbvie Barchart.com
Background: Endometriosis is a chronic, estrogen-dependent inflammatory disorder. It is associated with hormonal dysregulation, pelvic pain, and a reduced quality of life. Dietary factors may influence disease development and symptom …
Sensei finds Faeth | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
The advancement of nanotechnology has revolutionized reproductive healthcare worldwide. It has enabled the treatment of various conditions, such as infertility, endometriosis, ectopic pregnancies, erectile dysfunction, sexually transmitted infections (STIs), and …